0 69

Cited 1 times in

THYROID HORMONE REPLACEMENT REDUCES THE RISK OF CARDIOVASCULAR DISEASES IN DIABETIC NEPHROPATHY PATIENTS WITH SUBCLINICAL HYPOTHYROIDISM

Authors
 Changhwan Seo  ;  Seonghun Kim  ;  Misol Lee  ;  Min-Uk Cha  ;  Hyoungnae Kim  ;  Seohyun Park  ;  Hae-Ryong Yun  ;  Jong Hyun Jhee  ;  Youn Kyung Kee  ;  Seung Hyeok Han  ;  Tae-Hyun Yoo  ;  Shin-Wook Kang  ;  Jung Tak Park 
Citation
 Endocrine Practice, Vol.24(3) : 265-272, 2018 
Journal Title
 Endocrine Practice 
ISSN
 1530-891X 
Issue Date
2018
MeSH
Aged ; Asymptomatic Diseases ; Cardiovascular Diseases/epidemiology/etiology/*prevention & control ; Type 2/*complications/*drug therapy/epidemiology Diabetes Mellitus ; Diabetic Angiopathies/epidemiology/etiology/prevention & control ; Diabetic Nephropathies/complications/*drug therapy/epidemiology ; Female ; Follow-Up Studies ; *Hormone Replacement Therapy ; Humans ; Hypothyroidism/*drug therapy/epidemiology ; Male ; Middle Aged ; Retrospective Studies ; Risk Factors ; Thyroxine/*therapeutic use
Abstract
OBJECTIVE: Patients with diabetic nephropathy (DMN) have an increased risk of cardiovascular disease (CVD). However, strategies to reduce this risk are limited. Thyroid hormone replacement therapy (THRT) in patients with hypothyroidism has been shown to reduce several surrogate markers of CVD. Therefore, we performed a study to determine if THRT would reduce CVD risk in patients with subclinical hypothyroidism (SCH) and DMN. METHODS: This was a retrospective, nonrandomized study of patients with type 2 diabetes, DMN, and SCH. Those with known thyroid dysfunction or taking THRT at baseline were excluded. Patients receiving THRT for at least 180 days were included in the THRT group, while the remaining patients were assigned to the non-THRT group. The primary outcome was CVD events, which included coronary syndrome, cerebrovascular events, and peripheral artery diseases. RESULTS: Among the 257 patients, 83 (32.3%) were in the THRT group. The mean ages were 62.7 +/- 12.3 and 66.8 +/- 12.4 years in the THRT and non-THRT groups, respectively. The corresponding numbers of male patients were 32 (40.0%) and 94 (53.1%). During a mean follow-up of 38.0 +/- 29.2 months, 98 CVD events were observed. Acute coronary syndrome and cerebrovascular event prevalence rates were lower in the THRT group than the non-THRT group, but there was no difference for peripheral artery diseases. Multivariate Cox analysis revealed that THRT was independently associated with a decreased CVD event risk. CONCLUSION: THRT may decrease the risk of CVD in DMN patients with SCH. Randomized trials are needed to verify this finding. ABBREVIATIONS: CV = cardiovascular DMN = diabetic nephropathy eGFR = estimated glomerular filtration rate fT4 = free thyroxine HbA1c = glycosylated hemoglobin HR = hazard ratio hs-CRP = high-sensitivity C-reactive protein LDL-C = low-density lipoprotein cholesterol SCH = subclinical hypothyroidism T2DM = type 2 diabetes THRT = thyroid hormone replacement therapy TSH = thyroid-stimulating hormone.
Full Text
http://journals.aace.com/doi/10.4158/EP-2017-0017?code=aace-site
DOI
10.4158/ep-2017-0017
Appears in Collections:
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실)
Yonsei Authors
강신욱(Kang, Shin Wook) ORCID logo https://orcid.org/0000-0002-5677-4756
기연경(Kee, Youn Kyung)
김형래(Kim, Hyoung Rae)
박서현(Park, Seo Hyun)
박정탁(Park, Jung Tak) ORCID logo https://orcid.org/0000-0002-2325-8982
유태현(Yoo, Tae Hyun) ORCID logo https://orcid.org/0000-0002-9183-4507
윤해룡(Yun, Hae Ryong) ORCID logo https://orcid.org/0000-0002-7038-0251
이미솔(Lee, Mi Sol)
지종현(Jhee, Jong Hyun)
차민욱(Cha, Min Uk)
한승혁(Han, Seung Hyeok) ORCID logo https://orcid.org/0000-0001-7923-5635
Export
RIS (EndNote)
XLS (Excel)
XML
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/162145
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse